Exploring the Financial Advantages of Adding a CDK 4/6 Inhibitor to ER-Positive Breast Cancer.

Authors :: Busby, Leslie
Source :: Targeted Therapies in Oncology; Aug2024, Vol. 13 Issue 10, p56-56, 1p
Publication Year :: 2024

Subjects :: PROTEIN kinase inhibitors
AROMATASE inhibitors
HORMONE receptor positive breast cancer
COST effectiveness
METASTASIS
HORMONE therapy
QUALITY of life
PROGRESSION-free survival
CYCLIN-dependent kinases
OVERALL survival
MEDICAL care costs
CHEMICAL inhibitors

Tools